News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
498,868 Results
Type
Article (30665)
Company Profile (160)
Press Release (468043)
Multimedia
Podcasts (35)
Webinars (11)
Section
Business (141580)
Career Advice (620)
Deals (23645)
Drug Delivery (68)
Drug Development (56071)
Employer Resources (84)
FDA (13935)
Job Trends (11526)
News (240836)
Policy (23392)
Tag
Academia (2135)
Accelerated approval (3)
Adcomms (9)
Allergies (80)
Alliances (37953)
ALS (72)
Alzheimer's disease (1049)
Antibody-drug conjugate (ADC) (96)
Approvals (13997)
Artificial intelligence (250)
Autoimmune disease (16)
Automation (14)
Bankruptcy (172)
Best Places to Work (9597)
BIOSECURE Act (10)
Biosimilars (63)
Biotechnology (103)
Bladder cancer (69)
Brain cancer (22)
Breast cancer (242)
Cancer (1893)
Cardiovascular disease (149)
Career advice (557)
Career pathing (17)
CAR-T (114)
Cell therapy (328)
Cervical cancer (20)
Clinical research (47350)
Collaboration (760)
Compensation (245)
Complete response letters (12)
COVID-19 (1781)
CRISPR (29)
C-suite (232)
Cystic fibrosis (55)
Data (1973)
Decentralized trials (2)
Denatured (23)
Depression (36)
Diabetes (222)
Diagnostics (4924)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (26)
Drug discovery (91)
Drug pricing (79)
Drug shortages (23)
Duchenne muscular dystrophy (75)
Earnings (51426)
Editorial (25)
Employer branding (8)
Employer resources (75)
Events (72880)
Executive appointments (676)
FDA (15216)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (651)
Gene editing (72)
Generative AI (18)
Gene therapy (214)
GLP-1 (530)
Government (3529)
Grass and pollen (3)
Guidances (128)
Healthcare (15353)
Huntington's disease (12)
IgA nephropathy (19)
Immunology and inflammation (68)
Indications (29)
Infectious disease (1887)
Inflammatory bowel disease (106)
Inflation Reduction Act (8)
Influenza (39)
Intellectual property (84)
Interviews (72)
IPO (10313)
IRA (29)
Job creations (2352)
Job search strategy (503)
Kidney cancer (7)
Labor market (22)
Layoffs (249)
Leadership (9)
Legal (4588)
Liver cancer (63)
Lung cancer (276)
Lymphoma (123)
Machine learning (8)
Management (28)
Manufacturing (246)
MASH (59)
Medical device (13820)
Medtech (13824)
Mergers & acquisitions (13823)
Metabolic disorders (540)
Multiple sclerosis (65)
NASH (11)
Neurodegenerative disease (62)
Neuropsychiatric disorders (14)
Neuroscience (1479)
NextGen: Class of 2025 (5096)
Non-profit (3732)
Now hiring (19)
Obesity (267)
Opinion (132)
Ovarian cancer (66)
Pain (85)
Pancreatic cancer (72)
Parkinson's disease (124)
Partnered (18)
Patents (189)
Patient recruitment (109)
Peanut (42)
People (44793)
Pharmaceutical (44)
Pharmacy benefit managers (12)
Phase I (14108)
Phase II (20513)
Phase III (16425)
Pipeline (1033)
Policy (93)
Postmarket research (1818)
Preclinical (4807)
Press Release (54)
Prostate cancer (94)
Psychedelics (19)
Radiopharmaceuticals (230)
Rare diseases (257)
Real estate (4236)
Recruiting (33)
Regulatory (17036)
Reports (22)
Research institute (1987)
Resumes & cover letters (69)
Rett syndrome (4)
RNA editing (2)
RSV (25)
Schizophrenia (59)
Series A (111)
Series B (74)
Service/supplier (9)
Sickle cell disease (34)
Special edition (6)
Spinal muscular atrophy (124)
Sponsored (19)
Startups (2831)
State (1)
Stomach cancer (10)
Supply chain (54)
Tariffs (27)
The Weekly (11)
Vaccines (471)
Venture capitalists (27)
Weight loss (164)
Women's health (30)
Worklife (10)
Date
Last 7 days (710)
Last 30 days (2291)
Last 365 days (25777)
2025 (9324)
2024 (27730)
2023 (30939)
2022 (40031)
2021 (43091)
2020 (41931)
2019 (37851)
2018 (28798)
2017 (25081)
2016 (24042)
2015 (27693)
2014 (20575)
2013 (16850)
2012 (18380)
2011 (18571)
2010 (16720)
Location
Africa (470)
Alabama (32)
Alaska (5)
Arizona (156)
Arkansas (14)
Asia (31449)
Australia (4923)
California (4552)
Canada (1687)
China (510)
Colorado (211)
Connecticut (242)
Delaware (148)
Europe (67597)
Florida (772)
Georgia (187)
Idaho (47)
Illinois (491)
India (21)
Indiana (310)
Iowa (10)
Japan (149)
Kansas (85)
Kentucky (16)
Louisiana (11)
Maine (33)
Maryland (826)
Massachusetts (3409)
Michigan (166)
Minnesota (352)
Mississippi (2)
Missouri (77)
Montana (28)
Nebraska (21)
Nevada (57)
New Hampshire (66)
New Jersey (1526)
New Mexico (21)
New York (1442)
North Carolina (764)
North Dakota (8)
Northern California (1946)
Ohio (187)
Oklahoma (12)
Oregon (30)
Pennsylvania (1139)
Puerto Rico (9)
Rhode Island (31)
South America (701)
South Carolina (26)
South Dakota (1)
Southern California (1727)
Tennessee (97)
Texas (744)
United States (18494)
Utah (155)
Virginia (111)
Washington D.C. (52)
Washington State (363)
West Virginia (3)
Wisconsin (65)
498,868 Results for "410 medical innovation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
March 4, 2025
·
5 min read
Press Releases
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
April 29, 2025
·
3 min read
Press Releases
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
February 27, 2025
·
6 min read
Startups
Verdiva Jumps Into Hot Obesity Market With $410M Debut, Eyes Next-Gen Therapies
The company’s lead asset is a potentially first-in-class oral GLP-1 receptor agonist that has the potential to be dosed weekly, which according to CEO Khurem Farooq can help improve accessibility and affordability.
January 9, 2025
·
2 min read
·
Tristan Manalac
Drug Development
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure, Inc. today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
May 30, 2024
·
5 min read
Press Releases
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies
January 9, 2025
·
5 min read
Press Releases
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
February 12, 2025
·
7 min read
Drug Development
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Ocugen, Inc. announced a positive outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa clinical trial for OCU410 —a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration.
May 31, 2024
·
5 min read
Pharm Country
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Ocugen, Inc. announced that the Data Safety and Monitoring Board for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of OCU410ST in the dose-escalation phase of the study.
April 1, 2024
·
4 min read
Drug Development
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Ocugen, Inc. announced that the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
April 5, 2024
·
4 min read
1 of 49,887
Next
